- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
A new report from short seller firm S3 Analytics says shorts of cannabis stocks are down after a few positive announcements for the industry, including the approval of a new cannabis bill in the US.
A few developments in the marijuana industry have kept shorts of cannabis stocks at bay, a new report from research firm S3 Analytics stated.
On Wednesday (November 20), the firm published a study indicating short sellers of the marijuana public market were down US$272 million during the trading session, for the top 20 cannabis stocks tracked by S3 Analytics.
The report noted that short exposure for cannabis is up 16 percent so far this year for a total of US$389 million.
“Short selling is fairly concentrated to a handful of names, with only six stocks topping US$100 million of short interest,” the report said. It was authored by Ihor Dusaniwsky, managing director of predictive analytics at S3 Partners — the parent firm of S3 Analytics.
The researcher identified that the short market has seen a year-long trend of net short selling for the top 20 cannabis names and has so far reached US$1.41 billion.
“The increased short selling was needed to maintain overall short exposure in the sector as sector-wide price weakness decreased the notional value of the total short positions by just over US$1 billion,” Dusaniwsky wrote.
According to the report, a combination of the positive vote for the Marijuana Opportunity Reinvestment and Expungement Act (MORE Act) by the House Judiciary Committee helped cause the drop for shorts.
Alongside the vote, the following developments also caused the short dip:
- Canopy Growth (NYSE:CGC,TSX:WEED) obtaining a rate raise from the wealth management division of Bank of America (NYSE:BAC);
- Cronos Group (NASDAQ:CRON,TSX:CRON) investee Altria Group (NYSE:MO) upping its stake in the marijuana company to keep a 45 percent ownership of Cronos; and
- The Green Organic Dutchman (TSX:TGOD,OTCQX:TGODF) announcing distribution for its products in Alberta, Manitoba and Nova Scotia.
Dusaniwsky said the top shorted stocks from the leading pack of 20 were Cronos, Canopy Growth and GW Pharma (NYSE:GWPH).
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.